NCT07646145
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Enrollment increased: 30 → 50 participants
- Eligibility criteria expanded, about 21 words
- Secondary endpoints: details revised at 2 of 3 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
1-year disease-free survival rate(1-year DFS rate)
Timeframe: At 12 months after the first study treatment.
Secondary (3)
Disease-free survival
Overall Survival(OS)
Incidence and Severity of Treatment-emergent Adverse Events
Arms and interventions
Disitamab Vedotin Plus Intravesical Mitomycin CExperimental
Participants will receive intravenous disitamab vedotin in combination with intravesical mitomycin C according to the protocol-defined treatment schedule.
Drugs: Disitamab Vedotin, Mitomycin C (MMC)
Sites
1 site in 1 country
- Shanxi Provincial Cancer HospitalTaiyuan, Shanxi, China